BERKELEY HEIGHTS, N.J., Jan. 3, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (OTCBB:GNTA.OB) announced that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a comprehensive update of the Company's clinical research programs at the 5th Annual OneMedForum San Francisco 2012 on Wednesday, January 11th at 9:45 AM PST.
The conference will be held at The Sir Frances Drake Hotel on January 9-12, 2012. Further information about the Forum is available at: http://www.onemedplace.com/forum/.
About Genta
Genta Incorporated is a biopharmaceutical company with an innovative, diversified, and proprietary product portfolio that is principally focused on the treatment of patients with cancer. The Company is developing tesetaxel, a novel, orally absorbed taxane that is in the same class of drugs as paclitaxel and docetaxel. As the leading oral taxane in clinical development, tesetaxel has demonstrated anticancer activity in a broad program of clinical trials. The Company has announced that gastric (stomach) cancer and breast cancer will be the lead indications for Phase 3 registration studies. In other areas, Genta is exclusively marketing Ganite® (gallium nitrate injection) in the U.S, which is indicated for treatment of symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. The Company has developed proprietary oral formulations of the active ingredient in Ganite® that are being evaluated as potential treatments for diseases associated with accelerated bone loss, including bone metastases in oncology, and Paget's disease and osteoporosis in metabolic bone disease. For more information about Genta, please visit our website at: www.genta.com.
Safe Harbor
This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Such forward-looking statements include those that express plan, anticipation, intent, contingency, goals, targets, or future developments and/or otherwise are not statements of historical fact. The words "potentially," "anticipates," "expects," and similar expressions also identify forward-looking statements. The Company does not undertake to update any forward-looking statements. Factors that could affect actual results include, without limitation, risks associated with:
- the Company's ability to obtain necessary regulatory approval for its product candidates from regulatory agencies, such as the U.S. Food and Drug Administration and the European Medicines Agency;
- the safety and efficacy of the Company's products or product candidates;
- timing of the commencement and completion of any research program or clinical trials;
- the Company's assessment of its clinical trials;
- the Company's ability to develop, manufacture, license, or sell its products or product candidates;
- the Company's ability to enter into and successfully execute any license and collaborative agreements;
- the adequacy of the Company's capital resources and cash flow projections, the Company's ability to obtain sufficient financing to maintain the Company's planned operations, or the risk of bankruptcy;
- the adequacy of the Company's patents and proprietary rights;
- the impact of litigation that has been brought against the Company; and
- the other risks described under Certain Risks and Uncertainties Related to the Company's Business, as contained in the Company's Annual Report on Form 10-K and Quarterly Report on Form 10-Q.
There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2010 and its most recent quarterly report on Form 10-Q.